Skip to main content
SpringerLink
Log in

Olutasidenib: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Olutasidenib (REZLIDHIATM), an isocitrate dehydrogenase-1 (IDH1) inhibitor, is being developed by Rigel Pharmaceuticals for the treatment of relapsed or refractory (R/R) acute myeloid leukaemia (AML). Olutasidenib was recently approved in the USA for the treatment of adults with R/R AML with a susceptible IDH1 mutation as detected by a US Food and Drug Administration-approved test. This article summarizes the milestones in the development of olutasidenib leading to this first approval for R/R AML.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. U.S. Food & Drug Administration. FDA approves olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation [media release]. 1 Dec 2022. https://www.fda.gov/drugs.

  2. U.S. Food & Drug Administration. REZLIDHIA™ (olutasidenib) capsules, for oral use: US prescribing information. 2022. https://www.accessdata.fda.gov. Accessed 2 Feb 2023.

  3. Watts JM, Baer MR, Yang J, et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 2023;10(1):e46–58.

    Article  CAS  PubMed  Google Scholar 

  4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®): acute myeloid leukemia version 3.2022 - January 13, 2023. 2023. https://www.nccn.org/guidelines. Accessed 2 Feb 2023.

  5. Forma Therapeutics. Pipeline. 2023. https://www.formatherapeutics.com/pipeline. Accessed 2 Feb 2023.

  6. Rigel Pharmaceuticals. Rigel Pharmaceuticals and Forma Therapeutics announce licensing agreement for olutasidenib, a novel mutant IDH1 inhibitor for the potential treatment of relapsed or refractory acute myeloid leukemia [media release]. 2 Aug 2022. http://www.rigel.com.

  7. de Botton S, Fenaux P, Yee KWL, et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv. 2023. https://doi.org/10.1182/bloodadvances.2022009411.

    Article  PubMed  Google Scholar 

  8. de la Fuente MI, Colman H, Rosenthal M, et al. Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase Ib/II trial. Neuro Oncol. 2023;25(1):146–56.

    Article  PubMed  Google Scholar 

  9. Cortes JE, Fenaux P, Yee K, et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed/refractory mIDH1 acute myeloid leukemia. Results from a planned interim analysis of a phase 2 pivotal clinical trial. Blood. 2022;140(Suppl 1):6193–6.

    Article  Google Scholar 

  10. Abbott. Abbott Realtime IDH1: for in vitro diagnostic use. 2023. https://www.molecular.abbott/us/en/products/oncology/realtime-idh1. Accessed 2 Feb 2023.

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand

    Connie Kang

Authors
  1. Connie Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Connie Kang.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Connie Kang is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 229KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kang, C. Olutasidenib: First Approval. Drugs 83, 341–346 (2023). https://doi.org/10.1007/s40265-023-01844-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-023-01844-1

Search

Navigation